fig6
Figure 6. Exploratory prioritization of candidate genes and structure-based screening of compounds against FADS1. (A) Scoring framework applied to a broad exploratory pool of 192 unique genes derived from 439 gene-cell-trait association records. This pool included 159 associations meeting the formal Bayesian colocalization criterion and 280 additional associations retained through an exploratory LD-based screen. These numbers refer to association records, whereas 192 refers to unique genes. The resulting score was used to rank candidates for follow-up and does not represent the probability that a gene is causal or establish formal colocalization for every association contributing to the candidate pool; (B) Contributions of the prespecified MR-recurrence, pathway-enrichment, MCODE-module, PPI, and druggability components to the exploratory composite scores. HSPA1L ranked first (2.45), followed by FADS1 (2.15). Formal colocalization and SMR/HEIDI findings were evaluated separately and were not included as independent components of the composite score; (C-F) Expression patterns of selected prioritized genes in independent transcriptomic datasets. These observational expression results provide biological context but do not establish immune-cell mediation, effector-gene status, or a lipid-remodeling mechanism. FADS1 was highlighted because it showed additional transcriptomic and lipid-related support, despite HSPA1L having the highest composite score. Statistical significance in panels C-F is indicated as follows: *P < 0.05, **P < 0.01, and ***P < 0.001; ns, not statistically significant (P ≥ 0.05). For panel C, the indicated comparisons are preMetS vs. Normal and MetS vs. preMetS. For panels D-E, comparisons were made against the Normal group; for panel F, the Obese group was compared with the Lean group; (G) Exploratory structure-based virtual docking of five displayed compounds with an AlphaFold-predicted FADS1 protein structure. Xaliproden (a), Ono-RS-411 (b), lumacaftor (c), eltrombopag (d), and rolapitant (e) were selected from a 5,903-compound screening library based on predicted binding scores generated with AutoDock Vina. The compounds are shown for illustrative visualization and should not be interpreted as uniformly FDA-approved FADS1 ligands. The docking pocket was computationally defined using the grid centered at x = 1, y = -8, and z = 0, with dimensions of 35 Å × 30 Å × 34 Å. Ligands are shown in orange and FADS1 residues in cyan; hydrogen bonds and hydrophobic interactions are annotated. The docking screen was hypothesis-generating, and the complete ranked output was not available in the displayed panel. No biochemical binding assay, target-engagement experiment, substrate redocking validation, or functional activity assay was performed. The docking scores therefore indicate structural compatibility only and do not establish binding, target engagement, pharmacological activity, or therapeutic tractability. LD: Linkage disequilibrium; MCODE: Molecular Complex Detection; MetS: metabolic syndrome; MR: Mendelian randomization; ns: not statistically significant; preMetS: pre-metabolic syndrome; PPI: protein-protein interaction; T2D: type 2 diabetes.






